Skip to main content
For Healthcare Professionals

Reset all filters

51 - 53 of 53 results

Publications

Gathering our presentations, posters, abstracts, and publications, this educational resource offers materials across topics of interest in oncology. Explore the current topics below and revisit regularly to access the latest materials.

Infographic

DAREON®-8: A phase I, open-label, dose escalation/expansion trial of the DLL3-targeting T-cell engager, BI 764532, combined with first-line (1L) standard of care (platinum, etoposide, and anti-PD-L1 antibody) in patients (pts) with extensive-stage small cell lung carcinoma (ES-SCLC)
DAREON®-8: A Phase I dose escalation/expansion trial of BI 764532 (DLL3/CD3 IgG-like T-cell engager) plus standard of care (platinum, etoposide, and anti-PD-L1 antibody) in patients with extensive-stage small cell lung carcinoma (ES-SCLC)
Author(s): Peters et al.
SCLC DLL3/CD3 TcE Infographic
Download
Phase I dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager) + ezabenlimab (anti-PD-1 antibody) in patients with small cell lung cancer and other neuroendocrine carcinomas (NECs) expressing DLL3
Phase I dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T-cell engager) + ezabenlimab (anti-PD-1 antibody) in patients with small-cell lung cancer and other neuroendocrine carcinomas expressing DLL3
Author(s): Mazières et al.
SCLC, NEC/epNEC, LCNEC-L DLL3/CD3 TcE, PD-1 inhibitor Infographic
Download
First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3/CD3 IgG-like T cell engager, in patients with DLL3-positive small-cell lung cancer and neuroendocrine carcinoma
First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3/CD3 IgG-like T cell engager, in patients with DLL3-positive small-cell lung cancer and neuroendocrine carcinoma
Author(s): Wermke et al.
SCLC, NEC/epNEC, LCNEC-L DLL3/CD3 TcE Infographic
Download